Dyadic's RSV, malaria antibodies advance into preclinical animal studies
DYAI•Dyadic International’s C1-produced RSV and malaria antibodies entered preclinical animal studies led by the Gates Medical Research Institute. The studies began October 20, 2026, with results expected in the first quarter of 2027.
1. Animal studies begin
Dyadic International’s C1-produced RSV antibody RSM01 and malaria antibody MAM01 entered preclinical animal studies led by the Gates Medical Research Institute on October 20, 2026. The studies compare them with conventional mammalian-cell-produced versions, with results expected in the first quarter of 2027.
